ANALYTICAL CHEMISTRY AND STABILITY TESTING OF TREATMENT DRUGS NIH GUIDE, Volume 22, Number 11, March 19, 1993 RFP AVAILABLE: NO1DA-3-8301 P.T. 34 Keywords: Chemistry, Analytical Drugs/Drug Abuse Screening of Drugs/Agents National Institute on Drug Abuse The National Institute on Drug Abuse (NIDA) is soliciting proposals from qualified organizations having the capability to develop analytical methods, carry out quality control tests, and perform stability studies for the compounds and dosage forms to be used in the medications development program. The development of medications for the treatment of drug addiction is a major mission of NIDA. The NIDA has been providing potential treatment drugs to investigators for use in preclinical toxicology evaluation, pharmacological studies, and clinical trials. The treatment drugs include both bulk drug substances (e.g., ibogaine, buprenorphine, naltrindole) and dosage forms (e.g., buprenorphine alcoholic solution, 1-alpha-acetylmethadol concentrate, naltrexone sustained-release preparations). These drugs are acquired by the Government from private industry, Government contractors/grantees, or independent investigators. In order to ensure the identity, strength, quality and purity of these materials, the Government has been performing quality control tests before distributing them to the research community. The purpose of this procurement is to solicit a contractor to develop analytical methods, carry out quality control tests, dosage form preparation, and perform stability studies for the compounds and dosage forms to be used in the medications development program. The offeror is required to submit documentation of possession of a DEA research registration for Schedule I and II-V controlled substances with their response to the Request for Proposal (RFP). It is estimated that the RFP will result in a four-year incrementally funded completion-type contract with an option for a fifth year, as well as options for additional compound analysis and testing. Estimated issuance date of RFP No. NO1DA-3-8301 is March 22, 1993, and responses are due to be received in the Contracting Officer 45 calendar days thereafter. Written requests for copies of solicitations will be honored if received within twenty calendar days after issuance of the solicitation. Requests received after this period will be filled on a first-come, first-served basis until the supply is exhausted; however, there is no assurance that copies requested after the twentieth day will reach the requestor before the due date for receipt of responses. INQUIRIES Requests are to be forwarded to: Brenda Brooks, Contract Specialist National Institute on Drug Abuse Parklawn Building, Room 10-49 5600 Fishers Lane Rockville, MD 20857 .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |